论文部分内容阅读
目的探讨缬沙坦与诺和锐30联合应用对不同分期2型糖尿病肾病的治疗效果。方法 61例2型糖尿病肾病患者按尿蛋白定性,分为尿蛋白阴性而尿微量白蛋白排泄率≥20μg/min的微量白蛋白尿组(A组)38例和尿蛋白阳性的蛋白尿组(B组)23例,口服缬沙坦,根据血糖每日早晚2次餐前15 min皮下注射诺和锐30。治疗16周后观察缬沙坦与诺和锐30联合应用影响糖尿病肾病患者尿微量白蛋白排泄率情况。结果与治疗前比较,治疗后A组和B组的尿微量蛋白排泄率降低分别为(44.8±16.3)%和(29.0±23.7)%。两组比较差异有统计学意义(P>0.05)。结论缬沙坦与诺和锐30联合应用对2型糖尿病肾病患者的尿微量白蛋白有明显改善作用。
Objective To investigate the therapeutic effect of valsartan combined with Novartis 30 on type 2 diabetic nephropathy at different stages. Methods Sixty-one patients with type 2 diabetic nephropathy were divided into urinary protein-negative and microalbuminuria group (group A) with urinary albumin excretion rate ≥20μg / min and urine protein-positive proteinuria group (group A) B group) 23 cases, oral valsartan, according to blood glucose daily morning and evening 2 times 15 minutes before meals, subcutaneous injection of Noro Rui 30. After 16 weeks of treatment, observe the combination of valsartan and Novo-Rui 30 in patients with diabetic nephropathy urinary albumin excretion rate. Results Compared with those before treatment, the excretion of urinary microalbumin in groups A and B were (44.8 ± 16.3)% and (29.0 ± 23.7)%, respectively. The difference between the two groups was statistically significant (P> 0.05). Conclusions Combination of valsartan and Novartis 30 can significantly improve the urinary albumin in patients with type 2 diabetic nephropathy.